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OBJECTIVES We evaluated the vascular complications after hemostasis with arteriotomy closure devices
(ACD) versus manual compression after percutaneous coronary interventions (PCI).
BACKGROUND Previous clinical studies have indicated that ACD can be used for achievement of hemostasis
and early ambulation after PCI. This study investigated the safety of ACD in achieving
hemostasis after PCI compared with manual compression in a large cohort of consecutive
patients.
METHODS A total of 5,093 patients were followed after PCI was performed with the transfemoral
approach. Univariate and multivariate analysis were used to identify the predictors of vascular
complications with ACD (n 5 516) or with manual compression (n 5 5,892) as a hemostasis
option after sheath removal.
RESULTS The use of ACD was associated with a more frequent occurrence of hematoma compared
with manual compression (9.3 vs. 5.1%, p , 0.001). There was also a higher rate of significant
hematocrit drop (.15%) with ACD versus manual compression (5.2% vs. 2.5%, p , 0.001).
Similar rates of pseudoaneurysm and arteriovenous fistulae were noted with either hemostasis
technique. Vascular surgical repair at the access site was required more often with ACD versus
manual compression (2.5 vs. 1.5%, p 5 0.03).
CONCLUSIONS In this early experience with ACD after PCI, their use was associated with higher vascular
complication rates than hemostasis with manual compression. (J Am Coll Cardiol 2001;38:
638–41) © 2001 by the American College of Cardiology
After percutaneous coronary intervention (PCI), access site
complications may necessitate surgical repair or blood trans-
fusion (1–7). Sheath removal with manual compression can
be performed few hours after completion of PCI and
requires prolonged bed rest and delayed ambulation. Arte-
riotomy closure devices (ACD) may potentially allow earlier
sheath removal and ambulation with a similar or decreased
complication rate compared with manual compression.
See page 642
Although ACD have been tested in clinical studies before
their approval for clinical use (8–17), no large report exists
on their “real-world” application after approval.
This study reports on the safety of ACD use after PCI in
comparison with hemostasis with manual compression in a
large cohort of consecutive patients.
METHODS
We studied 5,098 patients who underwent 6,408 PCI
procedures at the Washington Hospital Center from Janu-
ary 1996 through June 1999. We excluded patients with
thrombolytic therapy, acute ST-elevation myocardial infarc-
tion (MI) or sheath size 10F or larger. All procedures were
performed by experienced interventional cardiologists who
performed both the arterial puncture and the ACD appli-
cation in the catheterization laboratory. Sheath removal
with manual compression was performed by dedicated
technicians according to the Hospital protocol (activated
clotting time [ACT] ,150 s).
Hemostasis with manual compression was performed
after 5,892 procedures (92%), whereas ACD were used in
516 procedures (8%) according to operator preference.
Angioseal (Daig, St. Paul, Minnesota) was used in 371
procedures; Duett (Vascular Solutions, Minneapolis, Min-
nesota) was used in 32 procedures; Vasoseal (Datascope
Corp., Montvale, New Jersey) was used in 6 procedures;
Prostar was used in 6 procedures, and Techstar was used in
101 procedures (Perclose Inc., Redwood City, California).
Femoral artery angiography was recommended before ACD
application.
Hospital charts were reviewed to obtain the clinical,
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procedural and laboratory results. The occurrence of vascu-
lar complications and major adverse cardiac events (MACE)
was recorded and adjudicated. All data were obtained from
the computerized database of the Cardiovascular Research
Foundation.
Statistics. Continuous variables were expressed as mean 6
SD and compared with unpaired Student t test. Categorical
variables were compared with Fisher exact test. Multivariate
logistic regression analysis was used to identify the indepen-
dent predictors of in-hospital vascular complications con-
trolling for baseline between-group differences. A two-
tailed p value ,0.05 was considered statistically significant.
RESULTS
Baseline patient characteristics are summarized in Table 1.
Patients treated with manual compression had a smaller
body size and a higher rate of previous MI and revascular-
ization procedures than the ACD group.
Procedural variables are summarized in Table 2. The
manual compression group was characterized by increased
use of debulking devices, longer procedural duration, lower
procedural ACT values and heparin doses. Platelet glyco-
protein IIb/IIIa inhibitors were used infrequently in both
groups.
In-hospital and vascular complications are shown in
Tables 3 and 4, respectively. In-hospital mortality and
MACE rates were similar between the two groups. Creatine
kinase-MB enzyme elevations after PCI were more frequent
in the ACD than in the manual compression group.
Pseudoaneurysm and arteriovenous fistulae occurred infre-
quently in both groups.
A significant drop of the hematocrit (.15%) occurred
more often in the patients with ACD than in the patients
with manual compression (5.2 vs. 2.5%, p , 0.001).
Hematoma developed more often with ACD than it did
with manual compression (9.3 vs. 5.1%, p , 0.001).
Accordingly, a hematoma with a hematocrit drop .15%
occurred 2.0 versus 0.6%, respectively (p , 0.001). Vascular
surgery for access site repair was also performed more often
in the ACD group compared with the manual compression
group (2.5 vs. 1.3%, p , 0.03).
Rates of hematoma and surgical access site repair were:
10.4% and 2.4% with Angio-Seal; 6.3% and 3.1% with
Duett; none (0 of 6) with Prostar; 7% and 2% with
Techstar, and 17% (1 of 6) for both complications with
Vasoseal. Due to the large sample size differences among the
above subsets, no statistical comparisons were performed
among them.
Independent predictors of vascular complications are
shown in Table 5 (multivariate analysis). Any vascular
complication was predicted by increased age, smaller body
size and female gender. Hematoma with a hematocrit drop
.15% was predicted by ACD use and smaller body size.
DISCUSSION
Vascular complications are common after cardiac catheter-
ization and PCI with the transfemoral approach. The use of
ACD may assist the operator in obtaining rapid hemostasis
with early ambulation and ideally would achieve potentially
fewer complications. Thus, the development of ACD may
create improved patient comfort or allow earlier discharge
from the hospital. Many types of ACD exist, and they use
Table 1. Baseline Characteristics
Patients/Procedures
Arteriotomy
Closure Device
Manual
Compression
p Value(n 5 497/516) (n 5 4,596/5,892)
Age (yrs) 64 6 11 64 6 12 0.920
Men 337 (68) 3,109 (68) 0.824
Hypertension 359 (70) 3,924 (67) 0.207
Diabetes mellitus 132 (26) 1,686 (29) 0.131
Insulin-treated diabetes 55 (11) 767 (13) 0.118
Family history of CAD 314 (61) 3,508 (60) 0.560
Hyperlipidemia 377 (73) 4,347 (74) 0.654
Chronic renal insufficiency 41 (8) 579 (10) 0.160
Dialysis 6 (1) 73 (1) 0.875
Body surface area (m2) 2.0 6 0.1 1.9 6 0.1 0.032
Left ventricular ejection fraction (%) 48 6 13 47 6 12 0.149
Unstable angina 339 (66) 3,827 (65) 0.863
Previous myocardial infarction 221 (43) 2,784 (47) 0.018
Previous CABG 174 (34) 2,246 (38) 0.041
History of PCI 213 (41) 2,893 (49) , 0.001
Peripheral vascular disease 119 (23) 1,417 (24) 0.722
Results are mean 6 SD or n (%).
CABG 5 coronary artery bypass graft; CAD 5 coronary artery disease; PCI 5 percutaneous coronary interventions.
Abbreviations and Acronyms
ACD 5 arteriotomy closure devices
ACT 5 activated clotting time
MACE 5 major adverse cardiac events
MI 5 myocardial infarction
PCI 5 percutaneous coronary interventions
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different materials and methods in achieving hemostasis.
Each device has evolved into various designs allowing
progressively easier delivery into the artery and more durable
closure of the arteriotomy.
Arteriotomy closure devices have been found to achieve
more rapid ambulation than manual compression with a
comparable complication profile between the two groups in
initial studies (13–19). However, no study has systematically
compared the use of ACD with hemostasis by manual
compression after PCI in a purely clinical setting, i.e. with
ACD use in a large cohort after device approval was
granted. In the present study, we found that ACD applica-
tion was associated with increased vascular complications.
Thus, the initial time to hemostasis that is gained with
ACD may be counterbalanced with the slightly increased
rate of certain vascular complications.
Several factors may be responsible for these results, and
they need to be addressed carefully. First, operator training
and experience with the ACD application is very important.
In our study, operators were very experienced with arterial
puncture; experience with ACD application was achieved
on an individual basis. Instruction was offered from the
manufacturers of the various ACD according to their
guidelines. A femoral angiogram was used in the majority of
cases, but there was no strict mandate for its performance.
Second, device-related limitations might have also contrib-
uted to the above results. Early types of ACD were used in
this study; the evolution of subsequent “generations” of
ACD may have properly rectified initial imperfections of
the “early” ACD types. Patient-related factors might also be
important, as indicated by the predictors of vascular com-
plications in the multivariate analysis of our study. Finally,
the absence of a specific ACT value as a guideline for sheath
removal in the ACD group might have also contributed to
the greater complication rate versus manual compression
(which was performed routinely when ACT ,150 s).
Although detailed information has not been provided
from any ACD study, it is possible that certain ACD may
be superior than others for certain patient subsets according
to clinical characteristics or femoral vascular anatomy. The
major imbalances in the number of patients treated with
each individual ACD prohibited any reliable comparison
among them within this study, but it should certainly be
carefully assessed in the future. For the very same reason,
the findings of this study may not be applicable in all ACD
types.
Further investigation should focus on each of these
parameters and attempt to improve the technical character-
istics, indications and operator-training for ACD use. In
addition, careful regulatory process with continued surveil-
lance after device approval and appropriate operator creden-
tialing should be considered. Meanwhile, operators should
apply ACD carefully, after they become considerably famil-
iar with the specific device.
Table 3. In-Hospital Results
Arteriotomy
Closure
Device
Manual
Compression p Value
Postprocedural mortality 1 (0.2) 49 (0.8) 0.114
Q-wave MI 0 (0) 7 (0.1) 0.433
Emergency/urgent CABG 10 (1.9) 87 (1.5) 0.399
Repeat PCI of target lesion 2 (0.4) 64 (1.1) 0.131
MACE 11 (2.1) 136 (2.3) 0.797
Non–Q-wave MI 79 (15) 707 (12) 0.008
CK-MB elevation
.3 3 normal
121 (23) 1,017 (17) , 0.001
Postprocedural renal
insufficiency
24 (4.9) 267 (4.7) 0.860
Results are n (%).
CABG 5 coronary artery bypass graft; CK-MB 5 creatine kinase-MB; MACE 5
major acute cardiac events (death, Q-wave MI or urgent revascularization); MI 5
myocardial infarction; PCI 5 percutaneous coronary intervention.
Table 4. Vascular Complications
Arteriotomy
Closure
Device
Manual
Compression p Value
Arteriovenous fistula 3 (0.6) 52 (0.9) 0.474
Pseudoaneurysm 5 (1.0) 58 (1.0) 0.968
Hematoma 48 (9.3) 300 (5.1) , 0.001
Hematocrit drop .15% 28 (5.2) 166 (2.5) , 0.001
Gastrointestinal bleeding 4 (0.8) 43 (0.7) 0.913
Major hematoma
(hematoma 1 hematocrit
drop .15%)
10 (2.0) 30 (0.6) , 0.001
Surgical repair (access site) 13 (2.5) 78 (1.3) 0.029
Results are n (%).
Table 2. Procedural Variables
Arteriotomy
Closure Device
Manual
Compression p Value
ACT maximum (s) 296 6 66 284 6 58 , 0.001
ACT final (s) 277 6 59 268 6 54 , 0.001
Total heparin dose (IU) 12,573 6 5,025 12,029 6 5,713 0.024
Procedure time (min) 63 6 34 77 6 57 , 0.001
Glycoprotein IIb/IIIa inhibitors 23 (5) 323 (6) 0.323
Devices used
Stent 562 (52) 5,567 (53) 0.862
Any debulking device 184 (17) 2,179 (21) 0.009
Balloon angioplasty alone 331 (31) 2,904 (26) , 0.001
Results are mean 6 SD or n (%).
ACT 5 activated clotting time.
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Study limitations. This study was limited because of its
retrospective, nonrandomized design. Specific types of
ACD were also selected by the operator. There was no
uniform, laboratory-initiated, standardized training for
ACD selection and application. The “learning curve” phase
of ACD needs to be taken into account when interpreting
these results. No conclusions regarding differences among
the various ACD should be drawn as a result of this study
because certain subgroups had a very limited patient num-
ber. Finally, these results may not be applicable in the newer
ACD “generations” or in the absence of a dedicated well-
trained sheath removal with manual compression team.
Conclusions. In this early experience with ACD after PCI,
their use was associated with higher vascular complication
rates than hemostasis with manual compression.
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